跳至主要内容
临床试验/ACTRN12613000347763
ACTRN12613000347763
已完成
未知

A randomised placebo-controlled clinical trial investigating the neurocognitive effects and in vivo mechanisms of action of Lacprodan(Registered Trademark) PL-20 in elderly participants with age-associated memory impairment.

Swinburne University of Technology0 个研究点目标入组 138 人2013年4月2日

概览

阶段
未知
干预措施
未指定
疾病 / 适应症
Age-associated Memory Impairment (AAMI)
发起方
Swinburne University of Technology
入组人数
138
状态
已完成
最后更新
6年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2013年4月2日
结束日期
2017年10月11日
最后更新
6年前
研究类型
Interventional
性别
All

研究者

入排标准

入选标准

  • Male or female.
  • \-Aged \>55 years.
  • \-Meets diagnostic criteria for age\-associated memory impairment: AAMI is defined on the basis of criteria first outlined by Crook et al: (i) A score \>25 on the Memory Complaint Questionnaire (MAC\-Q) and (ii) a score at \=1 standard deviation below the mean for healthy young adults on the Paired Associates Test from the Wechsler Memory Scale \- Revised (WMS\-R)
  • \-Willing and able to provide written informed consent.
  • \-Understands and is willing and able to comply with all study procedures.
  • \-English speaking.
  • \-Normal or corrected vision.
  • \-Must be right\-handed (applies only to the neuroimaging sub\-study).

排除标准

  • Dementia and/or MMSE score \<24\.
  • Neurological, cardiac, endocrine, gastrointestinal or bleeding disorders.
  • Psychiatric illness including mood disturbance/depression, as confirmed with a BDI\-II \>\=20\.
  • History of alcoholism and/or substance abuse.
  • Any known or suspected allergy to cow’s milk and/or lactose intolerance.
  • Participation in another clinical trial during the past 2 months.
  • Using any medications that could affect the outcome of the study including any pharmacological agents with known cognitive effects and diabetic medications.
  • Taking vitamins or herbal supplements regularly.

结局指标

主要结局

未指定

相似试验